Three scientific posters highlighting novel anti-virulence pharmacologic properties of oral ibezapolstat for C. difficile Infection; effects on toxin production, biofilm and the gut microbiome A ...
Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD -- Oral ...
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by ...
Five presentations will showcase nizubaglustat’s therapeutic potential in Lysosomal Storage Disorders. Nizubaglustat is currently being tested in two global Phase 3 studies for Niemann-Pick type C ...
5d
Faron's Bexmarilimab Data Accepted for Poster Presentation at the BSH Annual Scientific Meeting 2026
TURKU, FI / ACCESS Newswire / February 23, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies ...
Second-highest abstract submissions on record, 96 live oral presentations, more than 400 posters, and global leaders ...
Presenting your poster at a Labroots Virtual Event can provide valuable research insights and feedback from peers in the comfort of your home or office. Every Labroots virtual event features a virtual ...
A prospective natural history study for GM1 and GM2: 24-month data from the PRONTO study – Poster number 132, providing insights into disease progression in GM1 and GM2 gangliosidoses. A Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results